Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03B

Next Previous
X
Search
Trial Profile

A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03B

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belzutifan (Primary) ; Favezelimab/pembrolizumab (Primary) ; Lenvatinib (Primary) ; MK-4830 (Primary) ; Pembrolizumab (Primary) ; Pembrolizumab/Quavonlimab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MK-3475-03B; Substudy 03B
  • Sponsors Merck & Co; Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 01 Nov 2023 Planned End Date changed from 31 Oct 2025 to 7 Sep 2025.
    • 01 Nov 2023 Planned primary completion date changed from 31 Oct 2025 to 7 Sep 2025.
    • 01 Nov 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top